BACTERIAL MUTANTS FOR ENHANCED SUCCINATE PRODUCTION

Information

  • Patent Application
  • 20110177570
  • Publication Number
    20110177570
  • Date Filed
    June 30, 2009
    15 years ago
  • Date Published
    July 21, 2011
    13 years ago
Abstract
The present invention relates to a method for obtaining enhanced metabolite production in micro-organisms, and to mutants and/or transformants obtained with said method. More particularly, it relates to bacterial mutants and/or transformants for enhanced succinate production, especially mutants and/or transformants that are affected in the import and export of succinate.
Description

The present invention relates to a method for obtaining enhanced metabolite production in micro-organisms, and to mutants and/or transformants obtained with said method. More particularly, it relates to bacterial mutants and/or transformants for enhanced succinate production, especially mutants and/or transformants that are affected in the import and export of succinate.


Most environments are substrate limiting for micro-organisms, which has lead to very diverse and efficient carbon uptake systems (1). On the other hand, the excretion of end or intermediate products is less limiting for a micro-organism. Unless the excretion product has a competitive advantage (e.g. acetate excretion for acidification of the environment), excretion of certain end or intermediate products never needed to be as efficient, which has lead to a diverse selection of transport mechanisms (2,3).


From an industrial biotechnological perspective efficient excretion of an end-product can be a great advantage. It can lead to lower by-product formation, since the metabolism will not redirect carbon towards other exportable compounds and thus will lead to more easy to purify end-products. Additionally feedback inhibition of the pathway towards the product will be lowered, which logically leads to higher production rates. Both these production parameters, product purity and production rate, have previously been referred to as key parameters next to production yield (4-6) and were linked to the economically feasibility of a production process. The rising interest in industrial biotechnology originates in the increased awareness of the environmental impact of the existing industrial processes, the limited availability of fossil resources and the increasing political unrest that accompanies these evolutions. Up to now only few biotechnological processes are truly competitive with their chemical counterparts. In order to develop novel competitive processes a whole set of new techniques had to be developed, grouped in the so called discipline of ‘metabolic engineering’. This has already led to many new processes, in particular the development of succinate-production. Recent years many E. coli strains have been genetically modified with success, parallel to strain-development of Actinobacillus succinogenes, Mannheimia succiniciproducens, Anaerobiospirillum succiniciproducens.


Succinate as base chemical has first been pointed out by Greg Zeikus and coworkers in 1999 (7), after which the US Department of Energy (DOE) marked it as one of the top added value chemicals from renewable resources (4). Based on the petrochemical analogue, maleic anhydride, they have set the production price at custom-character0.45/kg. Nowadays, with the vastly increasing oil price, this analogue more than tripled in price. Herein lays the opportunity for bio-based chemicals to rise and become economical viable.


A second well defined parameter in the DOE report is the volumetric production rate, set at 2.5 g/l/h. These rates are not easily obtained. Low specific growth and production rates are thus far limiting to reach competitive succinic acid production, since high biomass concentrations are needed to obtain economical viable production rates.


A strategy that has never been tried before is pulling the metabolism towards a certain product instead of pushing it, leading to enhanced production rates. For this purpose the C4 transport systems lend themselves excellently.


A nice review on C4 dicarboxylic acid transport and sensors (8), groups the transporters in 5 large transporter families based on amino acid sequence similarities, the DctA family, the DcuAB family, DcuC family, CitT family and the TRAP family. This classification has been adopted and expanded by the transporter classification database, which summarizes all known transporters and membrane proteins (9) and has classified them in the class of the secondary transporters. All potential C4 dicarboxylic acid transporters are all then classified in 7 superfamilies: MFS, Dcu, DAACS, CSS, DASS, DcuC and AEC (3), of which the CSS superfamily does not have any representative in E. coli.


Looking more closely at the individual C4 dicarboxylic acid transport families, two main distinctions can be made, aerobic and anaerobic transport in Escherichia coli. While the DctA family mainly is operational in an aerobic environment, the DcuAB and DcuC family is operational in anaerobic conditions. Their function is closely related to the type of metabolism E. coli has in these conditions. Anaerobically, fumarate will function as a terminal electron acceptor, thus C4 dicarboxylic acids such as fumarate and malate will be interesting carbon sources for E. coli, while succinate is an end-product and will thus be preferably excreted (10). Transport in this condition will mainly be focussed on the import of fumarate, malate and other pathway intermediates and the export of succinate. Aerobically on the other hand, succinate is a crucial intermediate in the Krebs-cycle. It would thus be unfavourable for the cell to excrete succinate. In this case the cell is provided with a rather efficient succinate (C4-dicarboxylic acid) uptake system (DctA) which keeps the extracellular concentration low. It is also known that not only the DctA family, but a yet to be discovered carrier ensures the cell of succinate uptake (11). Enhancing succinate excretion would evidently mean, changing the whole expression scheme of these transporters.


Surprisingly, we found that by overexpression of the dcuC exporter gene, preferably overexpression under aerobic conditions, and by the knock out of the dctA importer gene, the production of succinate can be enhanced, especially of mutants that do have already a slightly higher succinate production.


A first aspect of the invention is a mutant and/or recombinant micro-organism comprising a genetic change leading to increased succinate export activity and decreased succinate import activity. A mutant as used here can be obtained by any method known to the person skilled in the art, including but not limited to UV mutagenesis and chemical mutagenesis. Some features may be obtained by classical mutagenesis, while others may be obtained by genetic engineering. Preferably the mutant strain is a recombinant strain, where all mutations are obtained by site directed mutagenesis and/or transformation. Preferably said mutant and/or recombinant is selected from a genus known to produce succinic acid. Even more preferably, said mutant and/or recombinant is an Escherichia coli strain.


Preferably, the genetic change in said mutant and/or recombinant strain is affecting in the dcuC exporter gene and the dctA importer gene, or in the orthologues thereof. Orthologues, as used here are genes in other genera, with a certain percentage identity at amino acid level, and a similar function. Preferably, said percentage identity, as measured by a protein BLAST, is at least 40%, even more preferably at least 50%, most preferably at least 60%. Beside the dcuC exporter gene and the dctA importer genes other importer of exporter genes might be affected.


Preferably, said genetic change is the replacement of the promoter of the dcuC exporter gene, and the knock out of the dctA importer gene. Even more preferably, the promoter of the dcuC exporter gene is replaced by a strong promoter, most preferably by a strong promoter functioning under aerobic conditions.


Preferably, the mutant and/or recombinant micro-organism, according to the invention, further comprises a genetic change in one or more of the genes selected from the group consisting of ackA, poxB, pta, arcA, sdhA, sdhB, sdhC, sdhD, iclR, citD, citE, citF, pckA, maeA, maeB, eda, edd gltA, ppc, sstT, ydjN, ygjE, citT/ybdS, ybhI, yfbS, yhjE and ydfJ. Possibly, other genes may be selected on the base of their importance in the metabolic network (Table II).


Another aspect of the invention is the use of a mutant and/or recombinant micro-organism comprising a genetic change leading to increased succinate export activity and/or decreased succinate import activity, in combination with a genetic change leading to increased succinate production to produce succinate. Increased succinate production is defined here as an increase in succinate productivity per unit of biomass or per unit of volume, and/or an increased extracellular succinate concentration, and/or an increase in succinate yield per unit of substrate. Preferably, said genetic change leading to increased succinate production is a genetic change in one or more of the genes selected from the group consisting of ackA, poxB, pta, arcA, sdhA, sdhB, sdhC, sdhD, iclR, citD, citE, citF, pckA, maeA, maeB, eda, edd gltA, ppc, sstT, ydjN, ygjE, citT/ybdS, ybhI, yfbS, yhjE and ydfJ. Possibly, other genes may be selected on the base of their importance in the metabolic network (Table II). Preferably, said use is the use under aerobic conditions.


Still another aspect of the invention is a mutant and/or recombinant micro-organism comprising a genetic change leading to increased succinate export activity and decreased succinate import activity for the production of succinate. Preferably, said mutant and/or recombinant micro-organism, further comprises a genetic change in one or more of the genes selected from the group consisting of ackA, poxB, pta, arcA, sdhA, sdhB, sdhC, sdhD, iclR, citD, citE, citF, pckA, maeA, maeB, eda, edd gltA, ppc, sstT, ydjN, ygjE, citT/ybdS, ybhI, yfbS, yhjE and ydfJ. Possibly, other genes may be selected on the base of their importance in the metabolic network (Table II).





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1: Gene knock out strategy (13) (top) and Gene knock in strategy (bottom)



FIG. 2: Construction of promoter delivery system for gene overexpression



FIG. 3: A: antibiotic resistance gene flanked with FRT sites, 50-nt homologies and restriction site regions; B and C: part of the gene of interest with the mutation; D: gene of interest with the mutation flanked by restriction site regions. 1: KO of the gene of interest; 2: mutant strain containing the point mutated gene of interest.



FIG. 4: Different succinate production rates (A) and yields (B) of E. coli MG1655 strains with modified C4-dicarboxylic acid transport: sdhAB: knock out of sdhAB; dcuC: overexpression of dcuC under control of promoter p37; dctA: knock out of dctA.



FIG. 5: Average growth rate of the wild type MG1655 and the dctA knock out strain under different conditions. The total amount of carbon is the same in each of the experiments (set to 0.5 c-mol/l). The p-values were obtained from a Student t test with 95% confidence interval.



FIG. 6: succinate yield in different genetic backgrounds. 0: wild type; * FNR: point mutation; 15: ΔpckA, 917: ΔmaeAB; 123467+: ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB; 6: ΔarcA; 123467 20+: ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB ΔdctA; 7: ΔsdhAB; 7B+: ΔsdhAB ΔFNR-pro37-dcuC; 7 20B+: ΔsdhAB ΔdctA ΔFNR-pro37-dcuC; 123467B+: ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB ΔFNR-pro37-dcuC; 123467 20B+: ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB ΔdctA ΔFNR-pro37-dcuC; 123467 20B+ edd: ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB ΔdctA ΔFNR-pro37-dcuC Δedd. The error bars show the standard deviation of at least five measurements in two fermentations.





EXAMPLES

Materials and Methods to the Examples


Strains


Escherichia coli MG1655 [λ, F, rph-1] was obtained from the Coli Genetic Stock Center (CGSC). It was explicitly checked to not have the fnr deletion, as some strains with this name have it (12). The different strains were preserved in 50% glycerol-LB growth medium solution.


Table 1 summarizes all used strains, with their respectively mutations









TABLE I





Summary of all constructed strains


Strains based in MG1655















FNR*


ΔpckA


ΔmaeAB


ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB


ΔarcA


ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB ΔdctA


ΔsdhAB


ΔsdhAB ΔFNR-pro37-dcuC


ΔsdhAB ΔdctA


ΔsdhAB ΔdctA ΔFNR-pro37-dcuC


ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB ΔFNR-pro37-dcuC


ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB ΔdctA ΔFNR-pro37-dcuC


ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB ΔdctA ΔFNR-pro37-dcuC Δedd


ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB ΔdctA ΔFNR-pro37-dcuC Δedd ΔcitDEF


ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB ΔdctA ΔFNR-pro37-dcuC Δedd ΔcitDEF ppc*


ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB ΔdctA ΔFNR-pro37-dcuC Δedd Δeda ΔcitDEF ppc*


ΔackA Δpta ΔpoxB ΔiclR ΔarcA ΔsdhAB ΔdctA ΔFNR-pro37-dcuC Δedd Δeda ΔcitDEF ppc*


gltA*









Media

The Luria Broth (LB) medium consisted of 1% tryptone peptone (Difco, Erembodegem, Belgium), 0.5% yeast extract (Difco) and 0.5% sodium chloride (VWR, Leuven, Belgium). Shake flask medium contained 2 g/l NH4Cl, 5 g/l (NH4)2SO4, 2.993 g/l KH2PO4, 7.315 g/l K2HPO4, 8.372 g/l MOPS, 0.5 g/l NaCl, 0.5 g/l MgSO4.7H2O, 16.5 g/l glucose.H2O, 1 ml/l vitamin solution, 100 μl/l molybdate solution and 1 ml/l selenium solution. The medium was set to a pH of 7 with 1M of KH2PO4.


Vitamin solution consisted of 3.6 g/l FeCl2.4H2O, 5 g/l CaCl2.2H2O, 1.3 g/l MnCl2.2H2O, 0.38 g/l CuCl2.2H2O, 0.5 g/l CoCl2.6H2O, 0.94 g/l ZnCl2, 0.0311 g/l H3BO4, 0.4 g/l Na2EDTA.2H2O and 1.01 g/l thiamine.HCl. The molybdate solution contained 0.967 g/l Na2Moa4.2H2O. The selenium solution contained 42 g/l SeO2. The minimal medium during fermentations contained 6.75 g/l NH4Cl, 1.25 g/l (NH4)2SO4, 1.15 g/l KH2PO4, 0.5 g/l NaCl, 0.5 g/l MgSO4.7H2O, 16.5 g/l glucose.H2O, 1 ml/l vitamin solution, 100 μl/l molybdate solution and 1 ml/l selenium solution with the same composition as described above.


Cultivation Conditions

A preculture from a single colony on a LB-plate was started in 5 ml LB medium during 8 hours at 37° C. on an orbital shaker at 200 rpm. From this culture, 2 ml was transferred to 100 ml minimal medium in a 500 ml shake flask, and incubated for 16 hours at 37° C. on an orbital shaker at 200 rpm. 4% inoculum was used in a 2 l Biostat B culture vessel with 1.5 l working volume (Sartorius-Stedim Biotech SA, Melsungen, Germany). The culture conditions were: 37° C., stirring at 800 rpm, gas flow rate of 1.5 l/min. The pH was maintained at 7 with 0.5M H2SO4 and 4M KOH. The exhaust gas was cooled down to 4° C. by an exhaust cooler (Frigomix 1000, Sartorius-Stedim Biotech SA, Melsungen, Germany). 10% solution of silicone antifoaming agent (BDH 331512K, VWR Int Ltd., Poole, England) was added when foaming rised during the fermentation (approx 10 μl). The off-gas was measured with an EL3020 off-gas analyser (ABB Automation GmbH, 60488 Frankfurt am Main, Germany).


Sampling Methodology

The bioreactor contains in its interior a harvest pipe (BD Spinal Needle, 1.2×152 mm (BDMedical Systems, Franklin Lakes, N.J.—USA) connected to a reactor port, linked outside to a Masterflex 14 tubing (Cole-Parmer, Antwerpen, Belgium) followed by a harvest port with a septum for sampling. The other side of this Masterflex 16 tubing is connected back to the reactor vessel. This system is referred to as the rapid sampling loop. During sampling, reactor broth is pumped around in the sampling loop. It has been estimated that, at a flow rate of 150 ml/min, the reactor broth needs 0.04 s to reach the harvest port and 3.2 s to re-enter the reactor. At a pO2 level of 50%, there is around 3 mg/l of oxygen in the liquid. The pO2 level should never go below 20%. Thus 1.8 mg/l of oxygen may be consumed during transit through the harvesting loop. Assuming an oxygen uptake rate of 0.4 g oxygen/g biomass/h (the maximal oxygen uptake rate found at μmax), this gives for 5 g/l biomass, an oxygen uptake rate of 2 g/l/h or 0.56 mg/l/s, which multiplied by 3.2 s (residence time in the loop) gives 1.8 mg/l oxygen consumption.


In order to stop the metabolism of cells during the sampling, reactor broth was sucked through the harvest port in a syringe filled with 62 g stainless steel beads precooled at −20° C., to cool down 5 ml broth immediately to 4° C.). Sampling was immediately followed by cold centrifugation (15000 g, 5 min, 4° C.). In the batch experiments, a sample for OD600 and extracellular measurements was taken each hour using the rapid sampling loop and the cold stainless bead sampling method. When exponential growth was reached, the sampling frequency was increased to every 20 minutes.


Analytical Methods

Cell density of the culture was frequently monitored by measuring optical density at 600 nm (Uvikom 922 spectrophotometer, BRS, Brussel, Belgium). Cell dry weight was obtained by centrifugation (15 min, 5000 g, GSA rotor, Sorvall RC-5B, Goffin Meyvis, Kapellen, Belgium) of 20 g reactor broth in pre-dried and weighted falcons. The pellets were subsequently washed once with 20 ml physiological solution (9 g/l NaCl) and dried at 70° C. to a constant weight. To be able to convert OD measurements to biomass concentrations, a correlation curve of the OD to the biomass concentration was made.


The concentrations of glucose and organic acids were determined on a Varian Prostar HPLC system (Varian, Sint-Katelijne-Waver, Belgium), using an Aminex HPX-87H column (Bio-Rad, Eke, Belgium) heated at 65° C., equipped with a 1 cm precolumn, using 5 mM H2SO4 (0.6 ml/min) as mobile phase. Detection was done by a dual-wave UV-VIS (210 nm and 265 nm) detector (Varian Prostar 325) and a differential refractive index detector (Merck LaChrom L-7490, Merck, Leuven, Belgium). Peak identification was done by dividing the absorptions of the peaks in both 265 and 210 nm, which results in a constant value, typical for a certain compound (formula of Beer-Lambert).


Genetic Methods

Plasmids were maintained in the host E. coli. DH5α (F, φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(rk, mk+), phoA, supE44, λ, thi-1, gyrA96, relA1), pKD46 (Red helper plasmid, Ampicillin resistance), pKD3 (contain an FRT-flanked chloramphenicol resistance (cat) gene), pKD4 (contains an FRT-flanked kanamycin resistance (kan) gene), and pCP20 (expresses FLP recombinase activity) plasmids were obtained from Prof. Dr. J-P Hernalsteens (Vrije Universiteit Brussel, Belgium). The plasmid pBluescript (Fermentas, St. Leon-Rot, Germany) was used to construct the derivates of pKD3 and pKD4 with a promoter library, or with alleles carrying a point mutation.


Mutations. The mutations consisted in gene disruption (knock-out, KO), replacement of an endogenous promoter by an artificial promoter (knock-in, KI), and point mutation (PM) (FIGS. 3). They were introduced using the concept of the Datsenko and Wanner (2000) (13) methodology.


Transformants carrying a Red helper plasmid were grown in 10-ml LB media with ampicillin (100 mg/L) and L-arabinose (10 mM) at 30° C. to an OD600 of 0.6. The cells were made electrocompetent by washing them with 50 ml of ice-cold water, a first time, and with 1 ml ice-cold water, a second time. Then, the cells were resuspended in 50 μl of ice-cold water.


Electroporation was done with 50 μl of cells and 10-100 ng of linear double-stranded-DNA product by using a Gene Pulser™ (BioRad) (600 OHMS, 25 μFD, and 250 volts). After electroporation, cells were added to 1-ml LB media incubated 1 h at 37° C., and finally spread onto LB-agar containing 25 mg/L of chloramphenicol or 50 mg/L of kanamycin to select antibiotic resistant transformants. The selected mutants were verified by PCR with primers upstream and downstream of the modified region and were grown in LB-agar at 42° C. for the loss of the helper plasmid. The mutants were tested for ampicillin sensitivity.


Linear double-stranded-DNA. The linear ds-DNA amplicons were obtained by PCR using pKD3, pKD4 and their derivates as template. The primers used had a part of the sequence complementary to the template and another part complementary to the side on the chromosomal DNA where the recombination has to take place. For the KO, the region of homology was designed 50-nt upstream and 50-nt downstream of the start and stop codon of the gene of interest. For the KI, the transcriptional starting point (+1) had to be respected. The PM were generated with primers that contained the mutation. PCR products were PCR-purified, digested with DpnI, repurified from an agarose gel, and suspended in elution buffer (5 mM Tris, pH 8.0).


Elimination of the Antibiotic Resistance Gene. The selected mutants (chloramphenicol or kanamycin resistant) were transformed with pCP20 plasmid, which is an ampicillin and chloramphenicol resistant plasmid that shows temperature-sensitive replication and thermal induction of FLP synthesis. The ampicillin-resistant transformants were selected at 30° C., after which a few were colony purified in LB at 42° C. and then tested for loss of all antibiotic resistances and of the FLP helper plasmid.


Point Mutations. The strategy consisted in two-steps, first a KO of the gene of interest and second to introduce the mutated gene in the same chromosomal location (FIG. 4). The gene of interest was amplified from the chromosomal DNA by PCR using primers containing the chosen mutation and flanked with restriction site regions. Two PCR products were generated from the same gene of interest, one from the promoter of the gene to 50-nt downstream of the mutation (C) and another from 50-nt upstream of the mutation to the stop codon (B). The mix of both PCR products was used as template to obtain the mutated gene flanked with restriction site regions (D). The antibiotic resistance genes (cat or kan) flanked with FRT sites were amplified from pKD3 or pKD4, respectively, by PCR with primers carrying the 50-nt homologies downstream of the stop codon of the gene of interest, the restriction site regions and 20-nt complementary to the template (A). The two PCR products A and D were digested with the appropriate restriction enzymes and introduced in a vector (p-Bluescript). After verifying the correct sequence of the gene, the inserted DNA was recovered by restriction enzyme digestion and used for further recombination.


Mathematical Methods
Metabolic Model

The metabolic network model of Lequeux et al. (2005) (14) was used. It includes glycolysis, with glucose transport by the phosphotransferase system (PTS), the pentose phosphate pathway, the Krebs cycle, and overflow metabolism. For each amino acid and nucleotide the anabolic reactions were included. Biosynthesis of lipopolysaccharides (LPS), lipid A, peptidoglycane, and the lipid bilayer are incorporated as well. The oxidative phosphorylation ratio (P/O) was set to 1.33 (15,16). The reactions and metabolites considered in the model are depicted in Tables 2 and 3 respectively.


Partial Least Squares

Partial Least Squares (PLS) regression has been performed in the software package R (17). This generalization of multiple linear regression is able to analyze data with strongly collinear and numerous independent variables as is the case for the elementary flux modes under study. Partial least squares regression is a statistical method that links a matrix of independent variables X with a matrix of dependent variables Y, i.e., the flux ratios and the succinate yield, respectively. Therefore, the multivariate spaces of X and Y are transformed to new matrices of lower dimensionality that are correlated to each other. This reduction of dimensionality is accomplished by principal component analysis like decompositions that are slightly titled to achieve maximum correlation between the latent variables of X and Y (18).


Elementary Flux Modes

The elementary flux modes of the stoichiometric E. coli model of Lequeux et al (2005) (14) were calculated by using Metatool 5 (19).


Example 1
Effect of Altered DctA and DcuC Activity in a sdhAB Knock Out Background

Three different promoters, P8, P37 and P55 were selected from a promoter bank. These P8, P37 and P55 are ranked from weak to strong. By evaluating in a chemostat, peculiarly enough higher acetate production rates were found in the strain with dcuC constitutively expressed with promoter P55 in comparison with the other promoters. Moreover, inclusion bodies were observed at the cellular poles of the dcuC-P55 strain. This leads to the conclusion that P55 is too strong as promoter, and the weaker P37 was used for further experiments.


The effect of the transporters was tested in an sdhAB knock out strain, which produces already some succinic acid. Neither enhanced production rate nor higher yield could be observed in strains in which solely DctA or DcuC activity was altered. The combination of altered import and export increased the specific production rate with about 55% and the yield with approximately 53% (FIG. 4).


Further investigation of the dctA single knock out has led to the conclusion that this strain grows faster on succinic acid than the wild type strain (FIG. 5). On glucose, pyruvate and the mixture of glucose and pyruvate the strains are growing equally fast. The experiment for the glucose-succinate mixture was repeated to determine a possible difference in growth rate of the two strains (in FIG. 4, there is a significant difference in case of 90% confidence, but not in case of 95% confidence). The results showed clearly that the two strains grow equally fast (p-value of 0.5). Only slight growth could be detected on fumarate, and no growth could be detected on malate.


Example 2
Effect of Altered DctA and DcuC Activity in Complex Genetic Backgrounds

Different mutants affecting the succinate pathway have been constructed, as shown in Table I. These mutations were combined with the DctA knock out and the ΔFNR-pro37-dcuC overproducing construction. The results on the succinate yield are shown in FIG. 6.









TABLE II





Reactions of the metabolic network (14)
















HK:
ATP + GLC → ADP + G6P


PGI:
G6P custom-character  F6P


PFK:
ATP + F6P → ADP + FBP


ALD:
FBP custom-character  G3P + DHAP


TP1:
DHAP custom-character  G3P


G3PDH:
PiOH + NAD + G3P custom-character  NADH + H + BPG


PGK:
ADP + BPG custom-character  ATP + 3PG


PGM:
3PG custom-character  2PG


ENO:
2PG custom-character  H2O + PEP


PyrK:
ADP + PEP → ATP + Pyr


PyrD:
NAD | Pyr | CoA → NADH | H AcCoA | CO2


CitSY:
H2O + AcCoA + OAA → CoA + Cit


ACO:
Cit custom-character  iCit


CitDH:
NAD + iCit custom-character  NADH + H + CO2 + aKGA


AKGDH:
NAD + CoA + aKGA → NADH + H + CO2 + SucCoA


SucCoASY:
ADP + PiOH + SucCoA custom-character  ATP + CoA + Suc


SucDH:
FAD + Suc → FADH2 + Fum


FumHY:
H2O + Fum custom-character  Mal


MalDH:
NAD + Mal custom-character  NADH − H + OAA


iCitL:
iCit → Suc + Glyox


MalSY:
H2O | AcCoA | Glyox → CoA | Mal


PEPCB:
H2O + PEP + CO2 → PiOH + OAA


PEPCBKN:
ATP + OAA → ADP + PEP + CO2


PyrMalCB:
NAD + Mal → NADH + H + Pyr + CO2


LacDH:
NADH + H + Pyr custom-character  NAD + Lac


PFLY:
Pyr + CoA → AcCoA + FA


EthDHLR:
2NADH + 2H + AcCoA custom-character  2NAD + CoA + Eth


AcKNLR:
ADP + PiOH + AcCoA custom-character  ATP + CoA + Ac


ActSY:
Pyr + Acdh → CO2 + Act


AcdhDH:
NADH + H + AcCoA custom-character  NAD + CoA + Acdh


EthDH:
NADH | H | Acdh custom-character  NAD | Eth


Resp:
1.33ADP + 1.33PiOH + NADH + H + 0.5O2 → 1.33ATP +



NAD + 2.33H2O


H2CO3SY:
H2O + CO2 custom-character  H2CO3


G6PDH:
NADP + G6P → NADPH + H + 6PGL


LAS:
H2O + 6PGL → 6PG


PGDH:
NADP + 6PG → NADPH + H + CO2 + Rl5P


PPI:
Rl5P custom-character  R5P


PPE:
Rl5P custom-character  Xu5P


TK1:
R5P + Xu5P custom-character  G3P + S7P


TA:
G3P + S7P custom-character  F6P + E4P


TK2:
Xu5P + E4P custom-character  F6P + G3P


FRPAS:
H2O + FBP → PiOH + F6P


R5P2R1P:
R5P custom-character  R1P


PTS:
GLC + PEP → G6P + Pyr


PPiOHHY:
PPiOH + H2O → 2PiOH


GluDH:
NADPH + H + aKGA + NH3 custom-character  NADP + H2O + Glu


GluLI:
ATP + NH3 + Glu → ADP + PiOH + Gln


GluSY:
NADPH + H + aKGA + Gln → NADP + 2Glu


AspSY:
ATP + H2O + Asp + Gln → AMP + PPiOH + Asn + Glu


AspTA:
OAA + Glu custom-character  aKGA + Asp


AspLI:
ATP + NH3 + Asp → AMP + PPiOH + Asn


AlaTA:
Pyr + Glu custom-character  aKGA + Ala


ValPyrAT:
Pyr + Val custom-character  aKIV + Ala


ValAT:
aKIV + Glu custom-character  aKGA + Val


LeuSYLR:
NAD + H2O + AcCoA + aKIV + Glu → NADH + H + CoA +



CO2 + aKGA + Leu


aKIVSYLR:
NADPH + H + 2Pyr → NADP + H2O + CO2 + aKIV


IleSYLR:
NADPH + H + Pyr + Glu + Thr → NADP + H2O + CO2 +



aKGA + NH3 + Ile


ProSYLR:
ATP + 2NADPH + 2H + Glu → ADP + PiOH + 2NADP +



H2O + Pro


SerLR:
NAD + H2O + 3PG + Glu → PiOH + NADH + H + aKGA +



Ser


SerTHM:
Ser + THF → H2O + Gly + MeTHF


H2SSYLR:
2ATP + 3NADPH + ThioredH2 + 3H + H2SO4 → ADP +



PPiOH + 3NADP + Thiored + 3H2O + H2S + PAP


PAPNAS:
H2O + PAP → AMP + PiOH


CysSYLR:
H2S + AcCoA + Ser → CoA + Cys + Ac


PrppSY:
ATP + R5P → AMP + PRPP


HisSYLR:
ATP + 2NAD + 3H2O + Gln + PRPP → 2PPiOH + PiOH +



2NADH + 2H + aKGA + His + AICAR


PheSYLR:
Glu + Chor → H2O + CO2 + aKGA + Phe


TyrSYLR:
NAD + Glu + Chor → NADH + H + CO2 + aKGA + Tyr


TrpSYLR:
Gln + Ser + Chor + PRPP → PPiOH + 2H2O + G3P + Pyr +



CO2 + Glu + Trp


DhDoPHepAD:
H2O + PEP + E4P → PiOH + Dahp


DhqSY:
Dahp → PiOH + Dhq


DhsSYLR:
Dhq custom-character  H2O + Dhs


ShiSY:
NADPH + H + Dhs custom-character  NADP + Shi


ShiKN:
ATP + Shi → ADP + Shi3P


DhqDH:
NADPH + H + Dhq → NADP + Qa


ChorSYLR:
PEP + Shi3P → 2PiOH + Chor


DhsDH:
Dhs → H2O + ProtoCat


ProtoCatDC:
ProtoCat → CO2 + Cat


BkaSYLR:
H2O + O2 + Cat → Bka


GallicSY:
NAD + Dhs → NADH + H + Gallic


ThrSYLR:
ATP + H2O + HSer → ADP + PiOH − Thr


MDAPSYLR:
NADPH + H + Pyr + SucCoA + Glu + AspSA → NADP +



CoA + aKGA + Suc + MDAP


LysSY:
MDAP → CO2 + Lys


MetSYLR:
H2O + SucCoA + Cys + MTHF − HSer → Pyr + CoA + Suc +



NH3 + Met + THF


AspSASY:
ATP + NADPH + H + Asp → ADP + PiOH + NADP +



AspSA


HSerDH:
NADPH + H + AspSA custom-character  NADP + HSer


CarPSY:
2ATP + H2O + H2CO3 + Gln → 2ADP + PiOH + Glu +



CarP


OrnSYLR:
ATP + NADPH + H + H2O + AcCoA + 2Glu → ADP +



PiOH + NADP + CoA + aKGA + Orn + Ac


ArgSYLR:
ATP + Asp + Orn + CarP → AMP + PPiOH + PiOH + Fum +



Arg


ThioredRD:
NADPH + Thiored + H custom-character  NADP + ThioredH2


H2O2ox:
2H2O2 → 2H2O + O2


FAD2NAD:
NAD + FADH2 custom-character  NADH − FAD + H


CoQ2NAD:
NADH + CoQ + H custom-character  NAD + CoQH2


NADH2NADPH
NADH + NADP custom-character  NAD + NADPH


AICARSYLR:
6ATP + 3H2O + CO2 + Asp + 2Gln + Gly + FA + PRPP



→ 6ADP + PPiOH + 6PiOH + Fum + 2Glu + AICAR


IMPSYLR:
FTHF + AICAR → H2O + THF + IMP


AMPSYLR:
Asp + GTP + IMP → AMP + PiOH + Fum + GDP


AdKN:
ATP + AMP custom-character  2ADP


ADPRD:
ADP + ThioredH2 → Thiored + H2O − dADP


dADPKN:
ATP + dADP → ADP + dATP


dADPPT:
H2O + dADP → PiOH + dAMP


IMPDH:
NAD + H2O + IMP → NADH + H + XMP


GMPSY:
ATP + H2O + Gln + XMP → AMP + PPiOH + Glu + GMP


GuKN:
ATP + GMP → ADP + GDP


GDPKN:
ATP + GDP → ADP + GTP


GDPRD:
ThioredH2 + GDP → Thiored + H2O + dGDP


dGDPKN:
ATP + dGDP → ADP + dGTP


dGDPPT:
H2O + dGDP → PiOH + dGMP


UMPSYLR:
O2 + Asp + PRPP + CarP → PPiOH + PiOH + H2O + CO2 +



UMP + H2O2


UrKN:
ATP + UMP → ADP + UDP


UDPKN:
ATP + UDP → ADP + UTP


CTPSY:
ATP + H2O + Gln + UTP → ADP + PiOH + Glu + CTP


CDPKN:
ATP + CDP custom-character  ADP + CTP


CDPPT:
H2O + CDP → PiOH + CMP


CMPKN:
ATP + CMP → ADP + CDP


CDPRD:
ThioredH2 + CDP → Thiored + H2O + dCDP


dCDPKN:
ATP + dCDP → ADP + dCTP


dCDPPT:
H2O + dCDP → PiOH + dCMP


dCTPDA:
H2O + dCTP → NH3 + dUTP


UDPRD:
ThioredH2 + UDP → Thiored + H2O + dUDP


dUDPKN:
ATP + dUDP → ADP + dUTP


dUTPPPAS:
H2O + dUTP → PPiOH + dUMP


dTMPSY:
MeTHF + dUMP → DHF + dTMP


dTMPKN:
ATP + dTMP → ADP + dTDP


dTDPKN:
ATP + dTDP → ADP + dTTP


dTDPPT:
H2O + dTDP → PiOH + dTMP


DHFRD:
NADPH + H + DHF → NADP + THF


FTHFSYLR:
NADP + H2O + MeTHF → NADPH + H + FTHF


GlyCA:
NAD + Gly + THF custom-character  NADH + H + CO2 + NH3 + MeTHF


MeTHFRD:
NADH + H + MeTHF → NAD + MTHF


FTHFDF:
H2O + FTHF → THF + FA


AcCoACB:
ATP + H2O + AcCoA + CO2 custom-character  ADP + PiOH + MalCoA


MalCoATA:
MalCoA + ACP custom-character  CoA + MalACP


AcACPSY:
MalACP → CO2 + AcACP


AcCoATA:
CoA + AcACP custom-character  AcCoA + ACP


C120SY:
10NADPH + 10H + AcACP + 5MalACP → 10NADP +



5H2O + 5CO2 + C120ACP + 5ACP


C140SY:
12NADPH + 12H + AcACP + 6MalACP → 12NADP +



6H2O + 6CO2 + C140ACP + 6ACP


C141SY:
11NADPH + 11H + AcACP + 6MalACP → 11NADP +



6H2O + 6CO2 + C141ACP + 6ACP


C160SY:
14NADPH + 14H + AcACP + 7MalACP → 14NADP +



7H2O + 7CO2 + C160ACP + 7ACP


C161SY:
13NADPH + 13H + AcACP + 7MalACP → 13NADP +



7H2O + 7CO2 + C161ACP + 7ACP


C181SY:
15NADPH + 15H + AcACP + 8MalACP → 15NADP +



8H2O + 8CO2 + C181ACP + 8ACP


AcylTF:
C160ACP + C181ACP + Go3P → 2ACP + PA


Go3PDH:
NADPH + H + DHAP custom-character  NADP + Go3P


DGoKN:
ATP + DGo → ADP + PA


CDPDGoSY:
CTP + PA custom-character  PPiOH + CDPDGo


PSerSY:
Ser + CDPDGo → CMP + PSer


PSerDC:
PSer → CO2 + PEthAn


GlnF6PTA:
F6P + Gln → Glu + GA6P


GlcAnMU:
GA6P custom-character  GA1P


NAGUrTF:
AcCoA + UTP + GA1P → PPiOH + CoA + UDPNAG


LipaSYLR:
ATP + 2CMPKDO + 2UDPNAG + C120ACP + 5C140ACP →



ADP + 2CMP + UMP + UDP + 6ACP + Lipa + 2Ac
















TABLE III





Metabolites of the metabolic network (14)

















2PG
C3H7O7P
2-phophoglycerate


3PG
C3H7O7P
3-phophoglycerate


6PG
C6H13O10P
6-phosphogluconate


6PGL
C6H11O9P
6-phosphogluconolacton


Ac
C2H4O2
Acetate


AcACP
C2H3OPept
Acetyl ACP


AcCoA
C23H34O17N7P3S
Acetyl CoA


Acdh
C2H4O
Acetaldehyde


ACP
HPept
Acyl carier protein


Act
C4H8O2
Acetoine


ADP
C10H15O10N5P2
Adenosine diphosphate


ADPHEP
C17H27O16N5P2
ADP-Mannoheptose


AICAR
C9H15O8N4P
Amino imidazole carboxamide ribonucleotide


aKGA
C5H6O5
Alpha keto glutaric acid


aKIV
C5H8O3
Alpha-keto-isovalerate


Ala
C3H7O2N
Alanine


AMP
C10H14O7N5P
Adenosine monophosphate


Ar5P
C5H11O8P
Arabinose-5-phosphate


Arg
C6H14O2N4
Arginine


Asn
C4H8O3N2
Aspartate


Asp
C4H7O4N
Asparagine


AspSA
C4H7O3N
Aspartate semialdehyde


ATP
C10H16O13N5P3
Adenosine triphosphate


BGalAse
C4.98H7.58O1.5N1.41
Beta-galactosidase



S0.0507


Biom
CH1.63O0.392N0.244
Biomass



P0.021S0.00565


Bka
C6H8O5
Beta ketoadipate


BPG
C3H8O10P2
1-3-biphosphoglycerate


C120ACP
C12H23OPept


C140ACP
C14H27OPept


C141ACP
C14H25OPept


C160ACP
C16H31OPept


C161ACP
C16H29OPept


C181ACP
C18H33OPept


CarP
CH4O5NP
Carbamoyl phosphate


Cat
C6H6O2
Catechol


CDP
C9H15O11N3P2
Citidine diphosphate


CDPDGo
C46H83O15N3P2
CDP-diacylglycerol


CDPEthAn
C11H20O11N4P2
CDP-ethanolamine


Chor
C10H10O6
Chorismate


Cit
C6H8O7
cisaconitate


CL
C77H144O16P2
Cardiolipin


CMP
C9H14O8N3P
Citidine monophosphate


CMPKDO
C17H26O15N3P
CMP-2-keto-3-deoxyoctanoate


CO2
CO2
Carbondioxide


CoA
C21H32O16N7P3S
Coenzyme A


CoQ
C14H18O4
Coenzyme Q, Ubiquinone (C5H8)n omitted


CoQH2
C14H20O4
Ubiquinol


CTP
C9H16O14N3P3
Citidine triphosphate


Cys
C3H7O2NS
Cysteine


dADP
C10H15O9N5P2
deoxy ADP


Dahp
C7H13O10P
Deoxy arabino heptulosonate


dAMP
C10H14O6N5P
deoxy AMP


dATP
C10H16O12N5P3
deoxy ATP


dCDP
C9H15O10N3P2
deoxy CDP


dCMP
C9H14O7N3P
deoxy CMP


dCTP
C9H16O13N3P3
deoxy CTP


dGDP
C10H15O10N5P2
deoxy GDP


dGMP
C10H14O7N5P
deoxy GMP


DGo
C37H70O5
Diacyl glycerol


dGTP
C10H16O13N5P3
deoxy GTP


DHAP
C3H7O6P
Dihydroxyaceton phosphate


DHF
C19H21O6N7
Dihydrofolate


Dhq
C7H10O6
Dehydroquinate


Dhs
C7H8O5
Dehydroshikimate


DNA
C9.75H14.2O7N3.75P
DNA composition


dTDP
C10H16O11N2P2
deoxy TDP


dTMP
C10H15O8N2P
deoxy TMP


dTTP
C10H17O14N2P3
deoxy TTP


dUDP
C9H14O11N2P2
deoxy UDP


dUMP
C9H13O8N2P
deoxy UMP


dUTP
C9H15O14N2P3
deoxy UTP


E4P
C4H9O7P
Erythrose-4-phosphate


Eth
C2H6O
Ethanol


F6P
C6H13O9P
Ftuctose-6-phosphate


FA
CH2O2
Formic Acid


FAD
C27H33O15N9P2
Flavine adeninen dinucleotide


FADH2
C27H35O15N9P2


FBP
C6H14O12P2
Fructose-1-6-biphosphate


FTHF
C20H23O7N7
Formyl tetrahydrofolate


Fum
C4H4O4
Fumarate


G1P
C6H13O9P
Glucose-1-phosphate


G3P
C3H7O6P
Glyceraldehyde-3-phosphate


G6P
C6H13O9P
Glucose-6-phosphate


GA1P
C6H14O8NP
D-glucosamine-6-phosphate


GA6P
C6H14O8NP
D-glucosamine-6-phosphate


Gallic
C7H6O5
Gallic acid


GDP
C10H15O11N5P2
Guanosine diphosphate


GLC
C6H12O6
Glucose


Glcg
C6H10O5
Glycogen


Gln
C5H10O3N2
Glutamine


Glu
C5H9O4N
Glutamate


Gly
C2H5O2N
Glycine


Glyox
C2H2O3
Glyoxylate


GMP
C10H14O8N5P
Guanosine monophosphate


Go3P
C3H9O6P
Glycerol-3-phosphate


GTP
C10H16O14N5P3
Guanosine triphosphate


H
H+
Hydrogene


H2CO3
CH2O3
Bicarbonate


H2O
H2O
Water


H2O2
H2O2


H2S
H2S
Hydrogene sulfide


H2SO4
H2O4S
Sulfuric acid


His
C6H9O2N3
Histidine


HSer
C4H9O3N
Homoserine


iCit
C6H8O7
isocitraat


Ile
C6H13O2N
Isoleucine


IMP
C10H13O8N4P
Inosine monophosphate


Lac
C3H6O3
Lactate


Leu
C6H13O2N
Leucine


Lipa
C110H196O32N2P2
Lipid A


Lipid
C40.2H77.6O8.41N0.771
Lipid composition



P1.03


Lps
C171H298O81N4P2
Lipo Poly sacharide


Lys
C6H14O2N2
Lysine


Mal
C4H6O5
Malate


MalACP
C3H3O3Pept
Malonyl ACP


MalCoA
C24H34O19N7P3S
Malonyl CoA


MDAP
C7H14O4N2
Meso-diaminopimelate


Met
C5H11O2NS
Methionine


MeTHF
C20H23O6N7
Methyleen tetrahydro folate


MTHF
C20H25O6N7
Methyl tetrahydrofolate


NAD
C21H28O14N7P2+
Nicotinamide adenine dinucleotide


NADH
C21H29O14N7P2


NADP
C21H28O17N7P3+
Nicotinamide adenine dinucleotide phosphate


NADPH
C21H29O17N7P3


NH3
H3N
Ammonia


O2
O2
Oxygen


OAA
C4H4O5
Oxaloacetate


Orn
C5H12O2N2.
Ornithine


PA
C37H71O8P
Phosphatidyl acid


PAP
C10H15O10N5P2
Phospho adenosine phosphate


PEP
C3H5O6P
Phosphoenolpyruvate


Peptido
C35H53O16N7
Peptidoglycane


PEthAn
C39H76O8NP
Phosphatidyl ethanolamine


PG
C40H75O9P
Phosphatidyl glycerol


Phe
C9H11O2N
Phenylalanine


PiOH
H3O4P
Phosphate


PPiOH
H4O7P2
Pyrophosphate


Pro
C5H9O2N
Proline


Prot
C4.8H7.67O1.4N1.37
Protein composition



S0.046


ProtoCat
C7H6O4
Protocatechol


PRPP
C5H13O14P3
5-phospho-alpha-D-ribosyl-1-pyrophosphate


PSer
C40H76O10NP
Phosphatidyl Serine


Pyr
C3H4O3
Pyruvate


Qa
C7H12O6
Quinate


R1P
C5H11O8P
Ribose-1-phosphate


R5P
C5H11O8P
Ribose-5-phosphate


Rl5P
C5H11O8P
Ribulose-5-phosphate


RNA
C9.58H13.8O7.95N3.95P
RNA composition


S7P
C7H15O10P
Sedoheptulose-7-phosphate


Ser
C3H7O3N
Serine


Shi
C7H10O5
Shikimate


Shi3P
C7H11O8P
Shikimate-3-phosphate


Suc
C4H6O4
Succinate


SucCoA
C25H36O19N7P3S
Succinyl CoA


THF
C19H23O6N7
Tetrahydrofolate


Thiored
Pept
Thioredoxin


ThioredH2
H2Pept
Reduced thioredoxin


Thr
C4H9O3N
Threonine


Trp
C11H12O2N2
Tryptophan


Tyr
C9H11O3N
Tyrosine


UDP
C9H14O12N2P2
Uridine diphosphate


UDPGlc
C15H24O17N2P2
UDP glucose


UDPNAG
C17H27O17N3P2
UDP N-acetyl glucosamine


UMP
C9H13O9N2P
Uridine monophosphate


UTP
C9H15O15N2P3
Uridine triphosphate


Val
C5H11O2N
Valine


XMP
C10H13O9N4P
Xanthosine-5-phosphate


Xu5P
C5H11O8P
Xylulose-5-phosphate









REFERENCES



  • 1. Postma, P. W., Lengeler, J. W., and Jacobson, G. R. (1993) Microbiological Reviews 57(3), 543-594

  • 2. Paulsen, I. T., Nguyen, L., Sliwinski, M. K., Rabus, R., and Saier, M. H. (2000) J. Mol. Biol. 301(1), 75-100

  • 3. Paulsen, I. T., Sliwinski, M. K., and Saier, M. H. (1998) J. Mol. Biol. 277(3), 573-592

  • 4. Werpy, T., Petersen, G., Aden, A., Bozell, J., Holladay, J., White, J., and Manheim, A. (2004) Top Value Added Chemicals from Biomass. Volume I: Results of Screening for Potential Candidates from Sugar and Synthesis Gas. In., US Department of Energy, Oak Ridge, USA

  • 5. McKinlay, J. B., Vieille, C., and Zeikus, J. G. (2007) Applied Microbiology and Biotechnology 76(4), 727-740

  • 6. Patel, M., Crank, M., Dornburg, V., Hermann, B., Roes, L., Husing, B., Overbeek, L., Terragni, F., and Recchia, E. (2006) Medium and Long-term Opportunities and Risks of the Biotechnological Production of Bulk Chemicals from Renewable Resources—The Potential of White biotechnology. In. The Brew report, University of Utrecht, Utrecht

  • 7. Zeikus, G. J., Jain, M. K., and Elankovan, P. (1999) Applied Microbiology and Biotechnology 51(5), 545-552

  • 8. Janausch, I. G., Zientz, E., Tran, Q. H., Kroger, A., and Unden, G. (2002) Biochimica Et Biophysica Acta-Bioenergetics 1553(1-2), 39-56

  • 9. Saier, M. H., Tran, C. V., and Barabote, R. D. (2006) Nucleic Acids Research 34, D181-D186

  • 10. Clark, D. P. (1989) Fems Microbiology Reviews 63(3), 223-234

  • 11. Davies, S. J., Golby, P., Omrani, D., Broad, S. A., Harrington, V. L., Guest, J. R., Kelly, D. J., and Andrews, S. C. (1999) Journal of Bacteriology 181(18), 5624-5635

  • 12. Soupene, E., van Heeswijk, W. C., Plumbridge, J., Stewart, V., Bertenthal, D., Lee, H., Prasad, G., Paliy, O., Charernnoppakul, P., and Kustu, S. (2003) Journal of Bacteriology 185(18), 5611-5626

  • 13. Datsenko, K. A., and Wanner, B. L. (2000) Proceedings Of The National Academy Of Sciences Of The United States Of America 97(12), 6640-6645

  • 14. Lequeux, G., Johansson, L., Maertens, J., Vanrolleghem, P., and Liden, G. (2005) Journal of Biotechnology 118, S121-S121

  • 15. Majewski, R. A., and Domach, M. M. (1990) Biotechnology and Bioengineering 35(7), 732-738

  • 16. Varma, A., and Palsson, B. O. (1993) Journal of Theoretical Biology 165(4), 503-522

  • 17. R-Development Core Team (2006).R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria

  • 18. Wold, S., Sjostrom, M., and Eriksson, L. (2001) Chemometrics and Intelligent Laboratory Systems 58(2), 109-130

  • 19. von Kamp, A., and Schuster, S. (2006) Bioinformatics 22(15), 1930-1931


Claims
  • 1. A mutant and/or recombinant micro-organism comprising a genetic change leading to increased succinate export activity and decreased succinate import activity.
  • 2. The mutant and/or recombinant micro-organism according to claim 1 wherein said micro-organism is an Escherichia coli strain.
  • 3. The mutant and/or recombinant micro-organism according to claim 1, wherein said genetic change affects the dcuC exporter gene and the dctA importer gene.
  • 4. The mutant and/or recombinant micro-organism according to claim 3, wherein said genetic change is the replacement of the promoter of the dcuC exporter gene and the knock-out of dctA importer gene.
  • 5. The mutant and/or recombinant micro-organism of claim 1, further comprising: a genetic change in one or more of the genes selected from the group consisting of ackA, poxB, pta, arcA, sdhA, sdhB, sdhC, sdhD, iclR, citD, citE, citF, pckA, maeA, maeB, eda, edd, gltA, ppc, sstT, ydjN, ygjE, citT/ybdS, ybhI, yJbS, yhjE and ydf.
  • 6. A process for producing succinate, wherein the improvement comprises: utilizing a mutant and/or recombinant micro-organism comprising a genetic change leading to increased succinate export activity and/or decreased succinate import activity, in combination with a genetic change leading to increased succinate production to produce succinate.
  • 7. A process for producing a succinate, wherein the improvement comprises: utilizing the mutant and/or recombinant micro-organism of claim 1 to produce succinate.
  • 8. The process according to claim 6, wherein said process is under aerobic conditions.
  • 9. The mutant and/or recombinant microorganism of claim 2, wherein the genetic change alters the dcuC gene and the dctA gene.
  • 10. The mutant and/or recombinant microorganism of claim 9, wherein the genetic change comprises replacing the promoter of the dcuC gene and knocking-out the dctA gene.
  • 11. The mutant and/or recombinant microorganism of claim 10, further comprising: a genetic change in one or more of the genes selected from the group consisting of ackA, poxB, pta, arcA, sdhA, sdhB, sdhC, sdhD, iclR, citD, citE, citF, pckA, maeA, maeB, eda, edd, gltA, ppc, sstT, ydjN, ygjE, citT/ybdS, ybhI, yfbS, yhjE, and ydfJ.
  • 12. The mutant and/or recombinant microorganism of claim 4, further comprising: a genetic change in one or more of the genes selected from the group consisting of ackA, poxB, pta, arcA, sdhA, sdhB, sdhC, sdhD, iclR, citD, citE, citF, pckA, maeA, maeB, eda, edd, gltA, ppc, sstT, ydjN, ygjE, citT/ybdS, ybhI, yfbS, yhjE, and ydfJ.
  • 13. The process of claim 7, wherein the process is conducted under aerobic conditions.
  • 14. A process for producing a succinate, wherein the improvement comprises: utilizing the mutant and/or recombinant microorganism of claim 2 to produce succinate.
  • 15. The process of claim 14, wherein the process is conducted under aerobic conditions.
  • 16. A process for producing a succinate, wherein the improvement comprises: utilizing the mutant and/or recombinant microorganism of claim 3 to produce succinate.
  • 17. The process of claim 16, wherein the process is conducted under aerobic conditions.
  • 18. A process for producing succinate, wherein the improvement comprises: utilizing the mutant and/or recombinant microorganism of claim 2 to produce succinate.
  • 19. The process of claim 18, wherein the process is conducted under aerobic conditions.
  • 20. A bacterial strain of the type having a dcuC gene and a dctA gene, wherein the bacterial strain is isolated, mutant, and/or recombinant, the improvement comprising: replacing the promoter of the dcuC gene and knocking-out the dctA gene of the bacterial strain so as to increase succinate export activity and decrease succinate import activity of the bacterial strain.
Priority Claims (1)
Number Date Country Kind
08159442.6 Jul 2008 EP regional
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/EP2009/058173 6/30/2009 WO 00 3/28/2011